Evaluation of plasma proteomic data for alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 3, 2013, Pages 233-243

  Llano, Daniel A ^a   Devanarayan, Viswanath ^b   Simon, Adam J ^c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b ABBOTT LABORATORIES   (United States)

^c AJ Simon Enterprises LLC   (United States)

Author keywords

ADNI, Rules Based Medicine; Alzheimer; biomarker; machine learning; mild cognitive impairment; proteomic; random forest

Indexed keywords

ALPHA 1 MICROGLOBULIN; ANGIOPOIETIN 2; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COMPLEMENT COMPONENT C3; FAS LIGAND; IMMUNOGLOBULIN M; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PEPTIDE YY; PREALBUMIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SOMATOMEDIN BINDING PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; BLOOD; CLASSIFICATION; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PREDICTIVE VALUE OF TESTS; PROTEOMICS;

EID: 84883288884     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31826d597a     Document Type: Article

References (60)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
2. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
4. Petersen R, Smith G, Waring S, et al. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997; 9(suppl 1):65-69.
5. Seppa? la? TT, Herukka SK, Ha? nninen T, et al. Plasma Ab42 and Ab40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry. 2010;81:1123-1127.
6. Le Bastard N, Leurs J, Blomme W, et al. Plasma amyloid-b forms in Alzheimer's disease and non-Alzheimer's disease patients. J Alzheimers Dis. 2010;21:291-301.
7. Lui JK, Laws SM, Li Q-X, et al. Plasma amyloid-b as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis. 2010;20:1233-1242.
8. Lewczuk P, Kornhuber J, Vanmechelen E, et al. Amyloid [beta] peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol. 2010;223:366-370.
9. Blennow K, De Meyer G, Hansson O, et al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging. 2009;13:205-208.
10. Roher AE, Esh CL, Kokjohn TA, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009;5:18-29.
11. Kester MI, Verwey NA, van Elk EJ, et al. Evaluation of plasma A[beta]40 and A[beta]42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31:539-540.
12. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Ab subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci. 2008;105:14052-14057.
13. Gupta VB, Laws SM, Villemagne VL, et al. Plasma apolipoprotein E and Alzheimer disease risk. Neurology. 2011;76: 1091-1098.
14. Lee KS, Chung JH, Choi TK, et al. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;28:281-287.
15. Kamer AR, Craig RG, Pirraglia E, et al. TNF-[alpha] and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. J Neuroimmunol. 2009;216:92-97.
16. Bermejo P, Mart?́n-Aragó n S, Bened?́ J, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett. 2008;117: 198-202.
17. Thambisetty M. Do extracellular chaperone proteins in plasma have potential as Alzheimer's disease biomarkers? Biomarkers Med. 2010;4:831-834.
18. Akatsu H, Ogawa N, Kanesaka T, et al. Higher activity of peripheral blood angiotensin-converting enzyme is associated with later-onset of Alzheimer's disease. J Neurol Sci. 2011; 300:67-73.
19. Gu? ntert A, Campbell J, Saleem M, et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis. 2010;21:585-596.
20. Mayeux R, Tang M, Jacobs D, et al. Plasma amyloid betapeptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46:412-416.
21. Mayeux R, Tang HL, Manly MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61:1185-1190.
22. Mehta PD, Pirttila T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of Amyloid {beta} proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-105.
23. Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma Amyloid {beta}-protein levels. Arch Neurol. 2003;60:958-964.
24. Kosaka T, Imagawa M, Seki K, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology. 1997;48:741-745.
25. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
26. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 1996;141:65-68.
27. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245-258.
28. Thambisetty M, Tripaldi R, Riddoch-Contreras J, et al. Proteome-based plasma markers of brain amyloid-b deposition in non-demented older individuals. J Alzheimers Dis. 2010;22: 1099-1109.
29. Li N-J, Liu W-T, Li W, et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin Biochem. 2010;43:992-997.
30. Soares HD, Chen Y, Sabbagh M, et al. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann NY Acad Sci. 2009; 1180:56-67.
31. Marksteiner J, Kemmler G, Weiss EM, et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2011;32:539-540.
32. Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006;129: 3042-3050.
33. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359-1362.
34. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
35. Strimmer K. A unified approach to false discovery rate estimation. BMC Bioinform. 2008;9:303.
36. Strimmer K. fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bionformatics. 2008;24:1461-1462.
37. Breiman L. Random forests. Machine Learning. 2001;45: 5-32.
38. Breiman L. Bagging predictors. Machine Learning. 1996;24: 123-140.
39. Cadima J, Cerdeira JO, Minhoto M. Computational aspects of algorithms for variable selection in the context of principal components. Comput Stat Data Anal. 2004;47:225-236.
40. Shi L, Campbell G, Jones WD, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotech. 2010;28:827-838.
41. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci. 2002;99:6562-6566.
42. Dupuy A, Simon R. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99:147-157.
43. R Foundation for Statistical Computing; 2011. Available at: http://www.r-project.org/. Accessed on September 13, 2012.
44. Kuhn M, Wing J, Weston S, et al. caret: Classification and Regression Training. R package version 4.83 2011 Available at: http://CRAN.R-project.org/ package=caret/.
45. Liaw A, Wiener M. Classification and regression by Random Forest. R News. 2002;2/3:18-22.
46. Daveau M, Jean L, Soury E, et al. Hepatic and extra-hepatic transcription of inter-a-inhibitor family genes under normal or acute inflammatory conditions in rat. Arch Biochem Biophys. 1998;350:315-323.
47. Falkenberg C, Blom A, Fries E, et al. Alpha 1-microglobulin and bikunin in rats with collagen II-induced arthritis: plasma levels and livier mRNA content. Scand J Immunol. 1997;46: 122-128.
48. Penders J, Delanghe JR. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta. 2004;346: 107-118.
49. Llano D, Li J, Waring J, et al. Cerebrospinal fluid cytokine dynamics differ between Alzheimer's disease patients and elderly controls. Alzheimer Dis Assoc Disord. 2011. [Epub ahead of print].
50. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann NY Acad Sci. 2010;1207:155-162.
51. Kondziella D, Go? thlin M, Fu M, et al. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. Neuroreport. 2009;20:825-827.
52. Yavuz BB, Yavuz B, Halil M, et al. Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer's disease. Int Psychogeriatr. 2008;20: 815-823.
53. Squitti R, Ventriglia M, Barbati G, et al. ?Free? copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm. 2007;114:1589-1594.
54. Salvaggio A, Periti M, Miano L, et al. Body mass index and liver enzyme activity in serum. Clin Chem. 1991;37:720-723.
55. Doruk H, Naharci MI, Bozoglu E, et al. The relationship between body mass index and incidental mild cognitive impairment, Alzheimer's disease and vascular dementia in elderly. J Nutr Health Aging. 2010;14:834-838.
56. Craig-Schapiro R, Kuhn M, Xiong C, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS ONE. 2011;6:e18850.
57. Wild E, Magnusson A, Lahiri N, et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011;3:RRN1231.
58. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90-94.
59. Llano DA, Laforet G, Devanarayan V. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25: 73-84.
60. Dickerson B, Salat D, Greve D, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404-411.